AEI's J.D. Kleinke examines the magnitude, symbolism, and likely impacts of the accounting rule included in the Accountable Care Act to regulate the administrative costs and profits of the health insurance industry.

With the new health-care plan, hospitals will be accountable for the patient health of their regional area, with no competition innovation is unlikely.

The new health care law will create a policy limbo that is likely to persist for decades, increasing uncertainty, ultimately discouraging investment and scientific risk-taking.

The political rhetoric surrounding embryonic stem-cell science reveals a widespread misconception of how medical products are created.

Perhaps it's the sweet California air, but the pervasive (though not universal) pessimism in biopharma these days is really bumming me out.  Consequently, I'd like to discuss three potential responses to difficult industry problems.

Of the many factors that make improving the health system difficult, few challenges are greater than the misty-eyed recollection – often from genuinely distinguished practitioners – of how great things used to be.  Doctors were highly regarded authority figures, pure and beloved, while patients were meek and grateful in the presence of such brilliance and expertise.

Innovation in drugs and medical devices in the U.S. is rampant.

Europe can improve its medical research and development by liberating the private sector.